Zealand Pharma A/S to Discuss Topline Results from Phase 1b Trial of Petrelintide Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Julian Harrison - BTIG - Analyst : Hi. Congratulations on these data, and thank you for take my questions. I'm curious if there was any time-dependent trend in the nausea adverse events. Did they happen earlier on in results from there, or was the timing more sporadic?

Question: Julian Harrison - BTIG - Analyst : Excellent, thank you. And then two forward-looking questions, if I may. I'm curious, have this study been longer, at what point would you have expected efficacy to plateau? And then also any comments with regards to expectations for body composition results in future readouts. That would be greatly appreciated.

Question: Julian Harrison - BTIG - Analyst : Thank you. That's very helpful. Congrats again.

Question: Michael Novod - Nordea Markets - Analyst : Thank you very much. I'm Michael Novod from Nordea. Just to note, I'm in an airport. Couple of questions from my side as well. So first of all, can you go into detail around whether you'll be able to take sort of dosing somewhat higher? Of course, we don't know your high dosage. But looking without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JUNE 20, 2024 / 6:00PM, ZELA.CO - Zealand Pharma A/S to Discuss Topline Results from Phase 1b Trial of Petrelintide Call at the Phase 2b, it's very comprehensive on the dosing side, maybe a bit of details on whether you can actually take dosing higher than what we're seeing currently? And then secondly, is there any rationale for the low BMI? BMI 29 is rather low, especially given the enrollment criteria going up much higher. And so any rationale behind why you ended up around 29? And then lastly, is it fair to assume also regarding muscle mass preservation, the link between -- it hasn't shown in receptors and insulin sensitivity, so thereby also explaining part of potential rationale around muscle mass preservation?

Question: Michael Novod - Nordea Markets - Analyst : Thank you. Congrats again. It's a really nice, David. Thank you.

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Hi. Congrats on the data, and thanks for taking my questions. So on the baselines, you highlighted the high percentage of means, but most of the data for women showing better weight loss. That means it's from [Clifton] drug. So I'm just curious as to the same trend holds for amylin as well. And does your prior data from part one or cagrilintide support this theory? And I had a couple of one-offs.

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Got it, thank you. And just a couple of more questions. So what would the magnitude of injection site reactions? I think you have in mind, but at this point, do you think that the injection site reactions are differentiated versus cagrilintide? And lastly, any color on metabolic parameters, and do you think it's comparable or better than Clifton monotherapy? The reason I ask is, these will be important if you wanted to have amylin as a monotherapy given the outcomes benefit seen with different drugs. Thank you and congrats on the data.

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Thank you.

Question: Suzanne van Voorthuizen - Van Lanschot Kempen N.V. - Analyst : Hi, team. Congrats on the data, and thanks for taking my questions. Firstly, on the dose levels, you are not disclosing yet, but you're saying you're within the relevant therapeutic band. So I was wondering for the Phase 2b, how those five doses differ from each other? If it's more in between doses or if there are other differences like frequency or titration? And my second question is on partnering. If you can elaborate once more on your thinking around the potential partnering of petrelintide and how this dataset fit into your thought process? Thank you.

Question: Suzanne van Voorthuizen - Van Lanschot Kempen N.V. - Analyst : Okay, thank you.

Question: Lucy Codrington - Jefferies - Analyst : Hi. Thanks for taking my questions. Just a few left. Firstly, I wonder if you can tell us in which dose cohort the patient that discontinued treatment was. And any indication as to why this patient may have been unable to tolerate whatever is now seems to tolerate it so well. Secondly, just to clarify, the BMI of 29, the initial slides say median but then the final -- the comparative slides said mean, so I just wanted to check with, is the mean and median both 29? And then for the Phase 2b, is the plan to include lifestyle interventions for the Phase 2b study or are you planning to have a similar kind clean trial for the Phase 2b yet? And if so, what's the rationale for that? yeah, I think I'll pause at there.

Question: Lucy Codrington - Jefferies - Analyst : Brilliant. Thank you very much.